Form 4: Royalty Pharma Executive Sells Shares

Royalty Pharma EVP Marshall Urist reported a sale of 9,098 Class A Ordinary Shares for approximately $55.18 per share, executed under a pre-arranged 10b5-1 trading plan.

Summary

• Marshall Urist, EVP of Research & Investments at Royalty Pharma plc, sold 9,098 Class A Ordinary Shares.
• The sale occurred on June 24, 2026, with a weighted average price of $55.1843 per share.
• The transactions were conducted under a Rule 10b5-1 trading plan adopted on February 12, 2026.
• The reported price is a weighted average, with individual sales ranging from $54.77 to $55.31.
• Urist also beneficially owns other securities, including limited partnership interests exchangeable into a significant number of Class A Ordinary Shares.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a slightly negative sentiment due to the sale of shares by a key executive, even though it was executed under a pre-planned 10b5-1 trading plan.

Negatives

• Sale of a significant number of shares by a key executive.

Risks

• Potential for negative market perception due to insider selling, even if conducted under a pre-planned 10b5-1 strategy.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding future performance. It solely reports on past transactions.

Industry Context

StockSavvy.ai notes that insider selling, even under a 10b5-1 plan, can sometimes be interpreted negatively by the market, regardless of the underlying strategic reasons. This filing is a standard disclosure of such a transaction within the pharmaceutical and biotech investment sector.

Stakeholder Impact

• Shareholders may view the sale by a senior executive with caution, potentially impacting short-term stock sentiment.
• The transaction does not appear to directly impact employees, customers, suppliers, or creditors based on the information provided.

Next Steps

• The holder undertakes to provide full information regarding the number of shares sold at each separate price upon written request.

Key Dates

Keywords

Royalty Pharma, RPRX, Form 4, Insider Trading, Share Sale, 10b5-1 Plan, Marshall Urist, Class A Ordinary Shares